1
|
Ramírez-Carracedo R, Hernández I, Moreno-Gómez-Toledano R, Díez-Mata J, Tesoro L, González-Cucharero C, Jiménez-Guirado B, Alcharani N, Botana L, Saura M, Zamorano JL, Zaragoza C. NOS3 prevents MMP-9, and MMP-13 induced extracellular matrix proteolytic degradation through specific microRNA-targeted expression of extracellular matrix metalloproteinase inducer in hypertension-related atherosclerosis. J Hypertens 2024; 42:685-693. [PMID: 38406874 PMCID: PMC10906209 DOI: 10.1097/hjh.0000000000003679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 01/08/2024] [Accepted: 01/22/2024] [Indexed: 02/27/2024]
Abstract
BACKGROUND Endothelial nitric oxide synthase (NOS3) elicits atheroprotection by preventing extracellular matrix (ECM) proteolytic degradation through inhibition of extracellular matrix metalloproteinase inducer (EMMPRIN) and collagenase MMP-13 by still unknown mechanisms. METHODS C57BL/6 mice lacking ApoE , NOS3, and/or MMP13 were fed with a high-fat diet for 6 weeks. Entire aortas were extracted and frozen to analyze protein and nucleic acid expression. Atherosclerotic plaques were detected by ultrasound imaging, Oil Red O (ORO) staining, and Western Blot. RNA-seq and RT-qPCR were performed to evaluate EMMPRIN, MMP-9, and EMMPRIN-targeting miRNAs. Mouse aortic endothelial cells (MAEC) were incubated to assess the role of active MMP-13 over MMP-9. One-way ANOVA or Kruskal-Wallis tests were performed to determine statistical differences. RESULTS Lack of NOS3 in ApoE null mice fed with a high-fat diet increased severe plaque accumulation, vessel wall widening, and high mortality, along with EMMPRIN-induced expression by upregulation of miRNAs 46a-5p and 486-5p. However, knocking out MMP-13 in ApoE/NOS3 -deficient mice was sufficient to prevent mortality (66.6 vs. 26.6%), plaque progression (23.1 vs. 8.8%), and MMP-9 expression, as confirmed in murine aortic endothelial cell (MAEC) cultures, in which MMP-9 was upregulated by incubation with active recombinant MMP-13, suggesting MMP-9 as a new target of MMP-13 in atherosclerosis. CONCLUSION We describe a novel mechanism by which the absence of NOS3 may worsen atherosclerosis through EMMPRIN-induced ECM proteolytic degradation by targeting the expression of miRNAs 146a-5p and 485-5p. Focusing on NOS3 regulation of ECM degradation could be a promising approach in the management of atherosclerosis.
Collapse
Affiliation(s)
- Rafael Ramírez-Carracedo
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
| | - Ignacio Hernández
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Av. Monforte de Lemos
| | - Rafael Moreno-Gómez-Toledano
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
- Universidad de Alcalá, Unidad de Fisiología, Departamento de Biología de Sistemas, Alcalá de Henares
| | - Javier Díez-Mata
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
| | - Laura Tesoro
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
| | - Claudia González-Cucharero
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
| | - Beatriz Jiménez-Guirado
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
| | - Nunzio Alcharani
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
| | - Laura Botana
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
| | - Marta Saura
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Av. Monforte de Lemos
- Universidad de Alcalá, Unidad de Fisiología, Departamento de Biología de Sistemas, Alcalá de Henares
| | - Jose L. Zamorano
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Av. Monforte de Lemos
- Departamento de Cardiología, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain
| | - Carlos Zaragoza
- Unidad Mixta de Investigación Cardiovascular, Departamento de Cardiología, Universidad Francisco de Vitoria, Hospital Ramón y Cajal (IRYCIS)
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Av. Monforte de Lemos
| |
Collapse
|
2
|
Reventun P, Toledano-Sanz P, Alcharani N, Viskadourou M, Morrison AC, Sabater-Lleal M, Wolberg AS, de Vries PS, Smith NL, Osburn WO, Arvanitis M, Lowenstein CJ. CD36 regulates factor VIII secretion from liver endothelial cells. Blood Adv 2024; 8:143-149. [PMID: 38157226 PMCID: PMC10787269 DOI: 10.1182/bloodadvances.2023010023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Accepted: 11/07/2023] [Indexed: 01/03/2024] Open
Affiliation(s)
- Paula Reventun
- Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
| | - Pablo Toledano-Sanz
- Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
| | - Nunzio Alcharani
- Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
- Departamento de Cardiología, Unidad de Investigación Cardiovascular, Hospital Ramón y Cajal, Universidad Francisco de Vitoria, Madrid, Spain
| | - Maria Viskadourou
- Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
| | - Alanna C. Morrison
- Department of Epidemiology, Human Genetics, and Environmental Sciences, Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX
| | - Maria Sabater-Lleal
- Unit of Genomics of Complex Disease, Institut d’Investigació Biomèdica Sant Pau, Barcelona, Spain
- Department of Medicine, Cardiovascular Medicine Unit, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Alisa S. Wolberg
- Department of Pathology and Laboratory Medicine and UNC Blood Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - Paul S. de Vries
- Department of Epidemiology, Human Genetics, and Environmental Sciences, Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX
| | - Nicholas L. Smith
- Department of Epidemiology, University of Washington, Seattle, WA
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA
- Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle, WA
| | - William O. Osburn
- Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
| | - Marios Arvanitis
- Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
| | - Charles J. Lowenstein
- Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
| |
Collapse
|
3
|
Moreno-Gómez-Toledano R, Delgado-Marín M, Cook-Calvete A, González-Cucharero C, Alcharani N, Jiménez-Guirado B, Hernandez I, Ramirez-Carracedo R, Tesoro L, Botana L, Sánchez-Esteban S, Diez-Mata J, Zamorano JL, Bosch RJ, Zaragoza C, Saura M. New environmental factors related to diabetes risk in humans: Emerging bisphenols used in synthesis of plastics. World J Diabetes 2023; 14:1301-1313. [PMID: 37664470 PMCID: PMC10473949 DOI: 10.4239/wjd.v14.i8.1301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/21/2023] [Accepted: 06/05/2023] [Indexed: 08/11/2023] Open
Abstract
BACKGROUND Diabetes mellitus (DM) is one of the largest global health emergencies of the 21st century. In recent years, its connection with environmental pollutants, such as bisphenol A (BPA), has been demonstrated; consequently, new structurally similar molecules are used to replace BPA in the plastics industry (BPS, BPF and BPAF). AIM To carry out a systematic review to allow coherent evaluation of the state of the art. Subsequently, a meta-analysis was performed to unify the existing quantitative data. METHODS Firstly, a systematic review was carried out, using the terms "(bisphenol) AND (Diabetes OR Hyperglycemia)", to maximize the number of results. Subsequently, three authors analyzed the set of articles. Finally, a meta-analysis was performed for each BP, using RevMan software. In addition, funnel plots were developed to study publication bias. RESULTS The systematic analysis of the literature revealed 13 recent articles (2017-2023) related to the study paradigm. The qualitative analysis showed interesting data linking diabetes to the three most widely used substitute BPs in the industry: BPS, BPF and BPAF. Finally, the meta-analysis determined a positive relationship with BPS, BPF and BPAF, which was only statistically significant with BPS. CONCLUSION There is a need to apply the precautionary principle, regulating the use of new BPs. Therefore, replacing BPA with BPS, BPF or BPAF is unlikely to protect the population from potential health risks, such as DM.
Collapse
Affiliation(s)
- Rafael Moreno-Gómez-Toledano
- Universidad de Alcalá,Department of Biological Systems/Physiology, Alcalá de Henares 28871, Spain
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - María Delgado-Marín
- Universidad de Alcalá,Department of Biological Systems/Physiology, Alcalá de Henares 28871, Spain
| | - Alberto Cook-Calvete
- Universidad de Alcalá,Department of Biological Systems/Physiology, Alcalá de Henares 28871, Spain
| | - Claudia González-Cucharero
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Nunzio Alcharani
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Beatriz Jiménez-Guirado
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Ignacio Hernandez
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Rafael Ramirez-Carracedo
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Laura Tesoro
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Laura Botana
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Sandra Sánchez-Esteban
- Universidad de Alcalá,Department of Biological Systems/Physiology, Alcalá de Henares 28871, Spain
| | - Javier Diez-Mata
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Jose Luis Zamorano
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Ricardo J. Bosch
- Universidad de Alcalá,Department of Biological Systems/Physiology, Alcalá de Henares 28871, Spain
| | - Carlos Zaragoza
- Cardiology Department, University Hospital Ramón y Cajal, Madrid 28034, Spain
- Laboratory of Cardiovascular Pathophysiology, Joint Translational Research Unit, University Francisco de Vitoria School of Medicine, Madrid 28034, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria-IRYCIS, Madrid 28034, Spain
| | - Marta Saura
- Universidad de Alcalá,Department of Biological Systems/Physiology, Alcalá de Henares 28871, Spain
| |
Collapse
|
4
|
Tesoro L, Hernández I, Ramírez-Carracedo R, Díez-Mata J, Alcharani N, Jiménez-Guirado B, Ovejero-Paredes K, Filice M, Zamorano JL, Saura M, Zaragoza C, Botana L. NIL10: A New IL10-Receptor Binding Nanoparticle That Induces Cardiac Protection in Mice and Pigs Subjected to Acute Myocardial Infarction through STAT3/NF-κB Activation. Pharmaceutics 2022; 14:pharmaceutics14102044. [PMID: 36297479 PMCID: PMC9608724 DOI: 10.3390/pharmaceutics14102044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 09/05/2022] [Accepted: 09/16/2022] [Indexed: 11/16/2022] Open
Abstract
(1) Background: Early response after acute myocardial infarction (AMI) prevents extensive cardiac necrosis, in which inflammation resolution, including expression of anti-inflammatory interleukin-10 (IL-10), may play a key role. (2) Methods: We synthesized NIL10, a micelle-based nanoparticle, to target IL-10 receptor in mice and pigs subjected to AMI. (3) Results: Administration of NIL10 induced cardiac protection of wild-type and IL-10 knockout mice and pigs subjected to AMI. Cardiac protection was not induced in IL-10-receptor null mice, as shown by a significant recovery of cardiac function, in which inflammatory foci and fibrosis were strongly reduced, together with the finding that resolving M2-like macrophage populations were increased after day 3 of reperfusion. In addition, anti-inflammatory cytokines, including IL-4, IL-7, IL-10, IL-13, IL-16, and IL-27 were also elevated. Mechanistically, NIL10 induced activation of the IL-10 receptor/STAT-3 signaling pathway, and STAT3-dependent inhibition of nuclear translocation of pro-inflammatory NF-ĸB transcription factor. (4) Conclusions: Taken together, we propose using NIL10 as a novel therapeutic tool against AMI-induced cardiac damage.
Collapse
Affiliation(s)
- Laura Tesoro
- Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28034 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
| | - Ignacio Hernández
- Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28034 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
| | - Rafael Ramírez-Carracedo
- Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28034 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
| | - Javier Díez-Mata
- Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28034 Madrid, Spain
| | - Nunzio Alcharani
- Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28034 Madrid, Spain
| | - Beatriz Jiménez-Guirado
- Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28034 Madrid, Spain
| | - Karina Ovejero-Paredes
- Departamento de Química, Facultad de Farmacia, Universidad Complutense (UCM), 28040 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERRES), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
| | - Marco Filice
- Departamento de Química, Facultad de Farmacia, Universidad Complutense (UCM), 28040 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERRES), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
| | - Jose Luis Zamorano
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
- Departamento de Cardiología, Hospital Universitario Ramón y Cajal (IRYCIS), 28034 Madrid, Spain
| | - Marta Saura
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
- Unidad de Fisiología, Departamento de Biología de Sistemas, Facultad de Medicina, Universidad de Alcalá, 28871 Madrid, Spain
| | - Carlos Zaragoza
- Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28034 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
- Correspondence: (C.Z.); (L.B.)
| | - Laura Botana
- Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28034 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
- Correspondence: (C.Z.); (L.B.)
| |
Collapse
|